The ADINA Act amends the Federal Food, Drug, and Cosmetic Act to require that labels for drugs intended for human use state and identify any ingredient that is, or is derived directly or indirectly from, a major food allergen or a gluten-containing grain. For gluten sources the bill explicitly references wheat, barley, rye, and their crossbred hybrids and requires the label to identify the specific grain type when applicable.
This change treats failure to disclose as misbranding under the FD&C Act and therefore brings noncompliant products within FDA’s existing enforcement tools. The bill forces manufacturers and upstream suppliers to tighten traceability and disclosure practices, creating immediate compliance consequences for drugmakers and possible safety benefits for patients with food allergies or celiac disease.
At a Glance
What It Does
The bill adds a new misbranding subsection to the FD&C Act that requires human drug labels to (1) state when they contain an ingredient that is a major food allergen or derived from one, and (2) identify each such ingredient and, if relevant, the specific gluten-containing grain. Non-disclosure is treated as misbranding.
Who It Affects
Prescription and over-the-counter drug manufacturers, ingredient suppliers, contract manufacturers, and the FDA. Pharmacists, clinicians, and patients with food allergies or celiac disease will also be directly affected by clearer labeling.
Why It Matters
This is the first federal proposal to extend food-allergen-style disclosure obligations into drug labeling, shifting traceability responsibility upstream and potentially changing how excipients and biological-derived ingredients are documented and communicated to users.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The ADINA Act creates a new labeling obligation for drugs intended for human use by inserting a misbranding clause into the FD&C Act. Under that clause, a drug label must explicitly state when the product contains any ingredient that is, or is derived directly or indirectly from, a ‘‘major food allergen’’ or from a gluten-containing grain.
For gluten sources the bill lists wheat, barley, rye, and their crossbred hybrids and requires the label to identify the specific grain type when applicable.
The bill is not limited to active pharmaceutical ingredients; its language covers any ingredient that meets the statutory test, including excipients, carriers, or components of biologic-derived materials. The phrase ‘‘derived directly or indirectly’’ reaches downstream processing steps and ingredients that may originate from allergenic foods but are present in modified or fractionated form in the finished drug product.
Failure to include the required statements and ingredient identifications renders the product misbranded under existing FD&C statutory mechanisms.Practical compliance will require manufacturers to map ingredient pedigrees and obtain supplier attestations sufficient to identify allergenic sources, and manufacturers may need to change labels, packaging inserts, and electronic product information. The bill gives the Secretary of Health and Human Services discretion to set the effective date but sets a default deadline of two years after enactment if the Secretary does not act.
Because the provision operates through the FD&C Act’s misbranding framework, FDA’s current enforcement tools—warnings, seizures, injunctions, and civil penalties—apply to violations.
The Five Things You Need to Know
The bill adds a new subsection 502(hh) to the FD&C Act making failure to disclose qualifying allergenic or gluten-derived ingredients a misbranding violation.
It covers any ingredient that is “derived directly or indirectly” from a major food allergen, language that potentially captures processed derivatives and components of biologic materials.
For gluten-containing grains the text explicitly names wheat, barley, rye, and their crossbred hybrids and requires labeling to identify the specific grain type when applicable.
Applicability begins on a date set by the HHS Secretary or, absent a Secretary determination, automatically 2 years after enactment.
Because the requirement is framed as misbranding, noncompliance exposes products to FDA enforcement remedies that already apply under the FD&C Act (recall, seizure, injunction, civil penalties).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — ADINA Act
This brief section provides the Act’s short name: the Allergen Disclosure In Non-food Articles Act, or ADINA Act. It is a formal convenience; it carries no operative requirements but is the heading under which the new labeling rule is published.
Mandates disclosure of allergenic and gluten-derived ingredients on drug labels
This is the operative change: the bill inserts subsection 502(hh) into the FD&C Act. It requires a drug label for human use to (1) state that the drug contains any ingredient that is a major food allergen or derived from one, and (2) identify each such ingredient. Where the ingredient is made from a gluten-containing grain, the label must also identify the grain type. Importantly, the language is ingredient-focused and not limited to active ingredients, which means excipients and carriers fall within the rule if they meet the ‘‘derived’’ threshold.
Secretary discretion with a two-year backstop
This subsection governs timing: the new 502(hh) applies on a date chosen by the HHS Secretary, but if the Secretary does not set a date it becomes effective two years after the Act’s enactment. That structure lets the agency issue guidance or phased compliance requirements before the default deadline, but it also creates a firm statutory fallback timeline for implementation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with food allergies or celiac disease — They gain clearer information about potential allergenic sources in medications, reducing exposure risk and informing safer prescribing and dispensing.
- Clinicians and pharmacists — Improved labeling reduces uncertainty when selecting or substituting medications for patients with known allergens, supporting safer medication use and counseling.
- Allergy advocacy and patient-safety organizations — The bill formalizes a disclosure expectation they have long argued for and provides a federal standard they can use for advocacy and education.
Who Bears the Cost
- Drug manufacturers (brand and generic) — They must audit supply chains, secure supplier attestations, test or trace ingredients, and update labels and labeling systems, generating compliance, legal, and operational costs.
- Ingredient suppliers and contract manufacturers — Suppliers will face increased documentation requests and possible requalification requirements to certify allergen origins, creating administrative burden and potential liability shifts.
- FDA and HHS — The agency must issue implementing guidance, adjudicate disputes over ‘‘derived’’ scope, and enforce the new misbranding standard, which will consume staff time and enforcement resources.
Key Issues
The Core Tension
The central dilemma is balancing patient safety through fuller allergen transparency against the operational and commercial burdens of tracing and disclosing ingredient origins: the bill improves information for allergic patients but forces manufacturers and suppliers to establish sometimes costly traceability and may pressure disclosure of sensitive formulation details without clear, narrow definitions of scope or thresholds.
The bill’s utility depends on definitional and scope choices left unspecified in the text. It uses the term “major food allergen” without defining it; in practice FDA will need to decide whether to adopt the FALCPA list (and whether to include milk, eggs, fish, shellfish, tree nuts, peanuts, soy, etc.) or to develop a different standard.
The undefined phrase “derived directly or indirectly” is the other major ambiguity: that wording can include highly processed derivatives or trace amounts present due to excipient sourcing, and resolving that will require detailed guidance on thresholds, testing, and acceptable supplier documentation.
Another tension is between disclosure and proprietary confidentiality. Manufacturers maintain trade-secret frameworks around formulations; requiring ingredient-level source attribution could force disclosure of upstream sources or processing steps manufacturers consider proprietary.
The bill frames the requirement as labeling rather than public ingredient-registration, but labeling obligations still risk exposing commercially sensitive chain-of-custody details or forcing reformulation where traceability cannot be certified.
Implementation also raises practical questions: how to treat contaminants or cross-contact versus intentionally added ingredients; whether biologic-derived materials (e.g., enzymes, plasma derivatives, cell-culture media) that originate from food sources are in scope; and how FDA will coordinate this new rule with global regulatory regimes and existing pharmaceutical nomenclature conventions (INN/USAN). Each of these areas will require agency-level decisions that materially affect compliance burden and patient protection outcomes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.